Greater Occipital Nerve and Cervical Region Injection in Patients With Trigeminal Neuralgia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04505280

Enrollment

Registered

2020-08-10

Start date

2020-07-01

Completion date

2022-12-30

Last updated

2023-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigeminal Neuralgia

Keywords

Trigeminal Neuralgia, Greater Occipital Nerve Block, Lidocaine

Brief summary

The aim of this study is to investigate the efficacy of greater occipital nerve block and cervical injections with lidocaine

Detailed description

After being informed about the study and potantiel risks, all patients giving informed consent will undergo randomization in 1:1 ratio to 1% lidocaine or 0.9% saline groups

Interventions

DRUGLidocaine 1% Injectable Solution

Greater occipital nerve and cervical region injections once a week for 4 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Classical Trigeminal Neuralgia

Exclusion criteria

* Secondary Trigeminal Neuralgia

Design outcomes

Primary

Measure	Time frame	Description
Efficacy on pain severity	3 months	Efficacy on pain scores. Visual Analogue Scale (VAS). VAS is a ten-point scale where zero refers to no pain and ten refers to maximal pain
Efficacy on pain frequency	3 months	Pain frequency per day

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026